A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

NCT00281294 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated early because the first phase didn't meet the endpoint.

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: Fontolizumab

Sponsor

PDL BioPharma, Inc.